Keiichi Fukuda Cuts Stake in Heartseed (219A) to 11.56% | Large Shareholding Report

A large shareholding report (EDINET filing) shows that Keiichi Fukuda has reduced his stake in Heartseed (219A) to 11.56%. The company, a bioventure spun out from Keio University, develops a treatment method involving transplantation of cardiac spheres, which are aggregates of heart muscle cells derived from iPS cells, into patients with severe heart failure. Fukuda's 11.56% stake represents a major shareholder position within the company's market capitalization, which commenced trading on the Tokyo Growth Exchange in July 2024. The holding has declined by 2.99 percentage points from the previous disclosure, with this sale representing an estimated ¥1.59 billion in share transfers.

Gradual Portfolio Reduction from Major Shareholder Status

Fukuda's reduction in shareholding reflects a phased approach to scaling back his position rather than a single transaction. His previous reported stake stood at 14.55%, and the current 11.56% represents approximately 3 percentage points of share sales. Since his initial disclosure following the company's IPO, Fukuda has been a principal shareholder, and his continued holding of over 10% of issued shares maintains his position as the largest investor in the company.

Scale Relative to Other Major Shareholders

Comparing Fukuda's holdings to other investors who have filed large shareholding reports on Heartseed reveals the extent of his prominence. Takumi Akiyama holds 4.87%, while SBI Investment Co., Ltd. holds 2.03%. Fukuda's 11.56% share significantly exceeds both parties and continues to position him as the leading shareholder with material influence over company direction.

Market Valuation Metrics and Price Positioning

At the disclosure date, Heartseed's share price was ¥2,322. The company's PER stands at 275.1x and its PBR at 7.38x, indicating elevated valuation multiples. These metrics reflect market expectations regarding the development trajectory and commercialization potential of the cardiac spheres therapy. Within the 52-week trading range, the current price position sits at 39%, placing it in the lower-to-middle portion of the year's price movements.

*Speculation: The gradual reduction in holding ratio by Fukuda, who has been a principal investor since the company's inception in a high-risk, high-return iPS cell therapy sector, may suggest portfolio rebalancing as the enterprise progresses through different growth phases.